Quick Answer
Oruka Therapeutics, Inc. reported Earnings Per Share Diluted of $3.87 (loss) per share for the year ending 2024.
- Oruka Therapeutics, Inc. showed a decrease of -945.9% in Earnings Per Share Diluted from 2023 to 2024.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $0.26 (loss) per share | Q2 2011: $0.03 per share | Q2 2012: $0.09 (loss) per share | Q2 2021: $0.34 (loss) per share | Q3 2021: $0.33 (loss) per share | Q1 2022: $0.23 (loss) per share | Q2 2022: $0.22 (loss) per share | Q3 2022: $0.16 (loss) per share | Q1 2023: $0.09 (loss) per share | Q2 2023: $0.10 (loss) per share | Q3 2023: $0.10 (loss) per share | Q1 2024: $2.21 (loss) per share | Q2 2024: $6.96 (loss) per share | Q3 2024: $1.46 (loss) per share | Q1 2025: $0.40 (loss) per share | Q2 2025: $0.46 (loss) per share.
- Over the full 4 years of available data (2021 to 2024), Oruka Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 178.4%.
- Historical annual values: Fiscal year 2024: $3.87 (loss) per share | Fiscal year 2023: $0.37 (loss) per share | Fiscal year 2022: $0.69 (loss) per share | Fiscal year 2021: $1.39 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: